Onlay Versus Inlay Humeral Component in Reverse Total Shoulder Arthroplasty
Launched by WILLIAM BEAUMONT HOSPITALS · Mar 16, 2022
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying two different methods of placing a component in the shoulder during a reverse total shoulder replacement surgery. The component helps the shoulder function better after surgery and can be placed in one of two ways: either on top of the upper arm bone (onlay) or inside the bone (inlay). The researchers want to find out if the way the component is placed affects how well patients can move their arm afterward, especially when raising it or turning it.
To participate in this trial, individuals need to be 18 years or older and have specific shoulder conditions, such as arthritis related to a torn rotator cuff. Participants should not have had previous shoulder surgeries or have certain other medical issues that could complicate the procedure. Those who join the study can expect to undergo the surgery, followed by a structured physical therapy program to help with recovery. This trial aims to provide valuable information that could improve shoulder surgery outcomes for future patients.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- * Patients undergoing primary reverse total shoulder arthroplasty with the following components:
- • 1. Onlay group: Ascend Flex stem, Perform Reversed standard +3 lateralized 25mm baseplate with standard 36 mm glenosphere or +6 lateralized 25mm baseplate with 39mm glenosphere
- • 2. Inlay group: Perform Stem Reverse, Perform Reversed +3 lateralized 25mm baseplate with standard 36mm glenosphere or +6 lateralized 25mm baseplate with 39mm glenosphere
- • Diagnosis of cuff tear arthropathy, massive cuff tear, or primary osteoarthritis with cuff tear
- • Negative external rotation lag sign, ability to externally rotate beyond neutral
- • Age 18 years or older
- Exclusion Criteria:
- • Revision arthroplasty
- • Prior open shoulder surgery
- • Concomitant tendon transfer (Latissimus Dorsi, Pectoralis Tendon, Lower Trapezius)
- • Diagnosis of rheumatoid arthritis, infection, acute trauma or instability
- • Patients not willing to undergo a standardized physical therapy protocol or home therapy program after surgical intervention
- • Patient anatomy does not accommodate the study implants per surgeon discretion
- • Pregnant, patient-reported
- • Minors (under 18 years of age)
- • Cognitively impaired based on a diagnosis of dementia, psychiatric disorder, or any cognitive deficit that will not allow for proper informed consent or answering of study questionnaires
About William Beaumont Hospitals
William Beaumont Hospitals is a leading healthcare provider known for its commitment to advancing medical research and improving patient care through innovative clinical trials. As a prominent sponsor in the field, Beaumont Hospitals focuses on conducting high-quality research that adheres to rigorous ethical standards and regulatory guidelines. With a multidisciplinary team of experienced researchers, clinicians, and support staff, the organization aims to foster collaboration and drive breakthroughs in medical science. Through its diverse portfolio of clinical trials, William Beaumont Hospitals is dedicated to enhancing treatment options and outcomes for patients across a wide range of medical conditions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Royal Oak, Michigan, United States
Patients applied
Trial Officials
Alex Martusiewicz, MD
Principal Investigator
Beaumont Health
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials